What is N-Acetyl Selank?
N-Acetyl Selank is a modified Selank label. The selected clinical report studied parent Selank, not a verified N-acetylated variant; its findings are included as related background.
Biological role or research focus
Modified-peptide evidence boundaries.
The intervention was parent Selank. Its report cannot confirm efficacy or safety of N-Acetyl Selank, and abstract-only methods limit interpretation.
Names you may encounter
Acetyl Selank · NA-Selank
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- N-acetylated Selank variant label
- Research focus
- Modified-peptide evidence boundaries
- Featured evidence
- Related parent compound · Human comparative report
- Source check
- October 4, 2026
Quick answers
- Is N-Acetyl Selank FDA approved?
- No. No FDA-approved drug contains N-Acetyl Selank. Source ↗
- Is N-Acetyl Selank safe?
- Unapproved modified form of Selank with no published human safety studies; even the parent peptide has only small studies and FDA safety concerns. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is N-Acetyl Selank banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Parent Selank compared with medazepam (2008) | 62 patients with generalized anxiety or neurasthenia in the parent-Selank report. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related parent compound · Human comparative report · 2008
Parent Selank compared with medazepam
What did this publication test, and what did it find?
- Population / model
- 62 patients with generalized anxiety or neurasthenia in the parent-Selank report.
- Study design
- Clinical comparison of Selank with medazepam using psychometric measures. Randomization and blinding were not established from the abstract.
- Main finding
- The parent-Selank report described similar anxiety-symptom responses across the compared treatments.
- Limits & context
- The intervention was parent Selank. Its report cannot confirm efficacy or safety of N-Acetyl Selank, and abstract-only methods limit interpretation.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming N-Acetyl Selank as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 0 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
No additional records were returned by this limited exact-name search. That is not evidence that no research exists; alternative scientific names may need investigation.
Repeat this PubMed search ↗Risks & interactions
Unapproved modified form of Selank with no published human safety studies; even the parent peptide has only small studies and FDA safety concerns.
No human studies of N-acetyl Selank were found. Small Russian reports involve the parent compound only, and FDA listed parent Selank among compounding substances with safety concerns. The modified form's safety is unknown.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Selank in generalized anxiety and neurasthenia (parent compound, 2008) ↗ · FDA: Bulk drug substances that may present significant safety risks ↗
Safety & what remains unknown
The absence of an exact-variant clinical study leaves human safety and formulation questions unresolved.
Evidence boundaries
The intervention was parent Selank. Its report cannot confirm efficacy or safety of N-Acetyl Selank, and abstract-only methods limit interpretation.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
No exact-variant human clinical publication was verified for this page’s selected evidence. This is an explicit evidence gap, rather than a claim that the modified product has been clinically validated.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
A terminal modification can change a peptide’s properties. Parent-compound observations do not establish the modified variant’s mechanism, exposure, or clinical effect.
Questions worth asking
- Did the cited clinical study test N-Acetyl Selank?
- What material, population, and route were actually studied?
- The intervention was parent Selank. Its report cannot confirm efficacy or safety of N-Acetyl Selank, and abstract-only methods limit interpretation.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did the cited clinical study test N-Acetyl Selank?
No. It tested parent Selank. The citation is clearly labeled related evidence and cannot validate the modified variant.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
